Tag: 36-month

BlueRock Therapeutics reports positive 36-month results from Phase I trial of bemdaneprocel for treating Parkinsons disease

Investigational cell therapy bemdaneprocel continues to demonstrate a favorable safety profile at…

Business Wire
By Business Wire